Verastem (VSTM) Non-Current Deffered Revenue (2011 - 2013)
Verastem's (VSTM) quarterly Non-Current Deffered Revenue came in at $16000.0 in Q2 2013, down 71.93% year-on-year from $57000.0 in Q2 2012, and down 42.86% quarter-over-quarter from $28000.0 in Q1 2013.
Verastem (VSTM) Non-Current Deffered Revenue (2011 - 2013) Analysis & Trends
Verastem's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $16000.0 for Q2 2013.
- On a quarterly basis, Non-Current Deffered Revenue fell 71.93% year-over-year to $16000.0 in Q2 2013; TTM through Jun 2013 was $16000.0, a 71.93% decrease from a year earlier, with the FY2012 full-year figure at $38000.0, down 48.65% from the prior year.
- Non-Current Deffered Revenue declined to $16000.0 in Q2 2013 per VSTM's latest filing, from $28000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $74000.0 in Q4 2011 and bottomed at $16000.0 in Q2 2013.
- The 3-year median for Non-Current Deffered Revenue is $47000.0 (2012), against an average of $46571.4.
- Across the five-year window, Non-Current Deffered Revenue plunged 48.65% in 2012 and plunged 71.93% in 2013, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $74000.0 in 2011, then plunged by 48.65% to $38000.0 in 2012, then tumbled by 57.89% to $16000.0 in 2013.
- Per Business Quant, the three latest VSTM Non-Current Deffered Revenue figures stand at $16000.0 (Q2 2013), $28000.0 (Q1 2013), and $38000.0 (Q4 2012).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 16,000.00 |
| Mar 31, 2013 | 28,000.00 |
| Dec 31, 2012 | 38,000.00 |
| Sep 30, 2012 | 47,000.00 |
| Jun 30, 2012 | 57,000.00 |
| Mar 31, 2012 | 66,000.00 |
| Dec 31, 2011 | 74,000.00 |